Wednesday, August 25, 2021

Colombian officials accidentally reveal details on Big Pharma's immunity for adverse reactions to COVID vaccines

Officials in Colombia accidentally published contracts from both Pfizer/BioNTech and AstraZeneca, detailing the multimillion-dollar deals and indemnification agreements struck between the South American nation and the pharmaceutical giants to import around 25 million combined doses of their COVID-19 vaccines.

The 132-page file details the contractual agreement established between the Colombian government and the two pharmaceutical companies, with AstraZeneca's contract being signed on December 16, 2020, and Pfizer's on February 2, 2021.

Colombian officials agreed to pay AstraZeneca $6 per dose, ordering a total of 9,984,000 shots from the Oxford-based operation and costing $59,904,000.

All told, the Colombian government shelled out a hefty $239,910,840 for 24,984,570 doses of COVID-19 vaccines, corresponding to 12,492,285 citizens being able to become "Fully vaccinated" against the virus.

Pfizer explicitly stated that "The long-term effects and efficacy of the Vaccine are not currently known and that there may be adverse effects of the Vaccine that are not currently known." The Colombians were forced to acknowledge that the jab has unknown effects since it is "Being rapidly developed due to the emergency circumstances of the COVID-19 pandemic."

The AstraZeneca contract made similar demands on the Colombian authorities, adding an express indemnification requirement "For death, physical, mental, or emotional injury, illness, disability, or condition arising from the use or administration of the Vaccine."

The Colombian supreme court blunder leading to the revelation of the vaccine contracts, is not the first time that pharmaceutical companies have had the details of their international agreements made public against their wishes.

https://www.lifesitenews.com/news/columbian-officials-accidentally-reveal-details-on-big-pharmas-immunity-for-adverse-reactions-to-covid-vaccines/ 

No comments: